Valvular & structural heart disease
GLP-1 receptor agonists and clinical outcomes in patients with type 2 diabetes undergoing transcatheter aortic valve implantation
Main finding · Survival probabilityResult — go to the resultHazard ratio 0.708 95% CI 0.583–0.859Authors' conclusion
In patients with T2D undergoing TAVI, GLP1-RA use is associated with significant survival benefits and improved cardiorenal outcomes. However, these findings are limited by the observational design, high comorbidity burden, lack of data on medication compliance, and specific cause of death. Prospective trials are warranted to confirm these benefits.
Study context
- Population
- Adults (≥18 years) with T2D who underwent transcatheter aortic-valve implantation (TAVI) (2015–2023)Propensity score matching (PSM) yielded 1101 patients per group
- Participants
- 25,184 adults
- Exposure
- GLP1-RA initiation within 14 days post-TAVI vs no GLP1-RA
- GLP1-RA usersn = 1,101
- Non-usersn = 1,101reference
- Outcome
- Survival probability
- Follow-up
- From one-month post-TAVI until the most recent
Methodological detailsTriNetX network, 1:1 propensity score matching
- TriNetX network
- 1:1 propensity score matching
Main finding
As reported in the abstract
Hazard ratio
0.708
95% CI 0.583–0.859
GLP1-RA usersvs non-users
HR 0.708 (95% CI 0.583–0.859)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| All-cause hospitalizationLower with GLP1-RA use | 0.790 (0.706–0.885) | |
| Major cardiovascular eventsLower with GLP1-RA use | 0.849 (0.749–0.963) | |
| Acute heart failure exacerbationLower with GLP1-RA use | 0.785 (0.677–0.909) | |
| Acute kidney injuryLower with GLP1-RA use | 0.843 (0.719–0.988) | |
| Major kidney eventsLower with GLP1-RA use | 0.665 (0.510–0.866) | |
| 0.512Hazard ratio (log scale) |
| Outcome | GLP1-RA users | Non-users |
|---|---|---|
| Matched cohort characteristics and follow-up | mean follow-up duration 2.2 ± 1.1 years | mean follow-up duration 2.6 ± 1.8 years |
- Matched cohort characteristics and follow-up — Mean age
- 73 years
- Matched cohort characteristics and follow-up — Female
- 39%
Acute myocardial infarction, cerebral infarction, cardiac arrest
- No differences observed
Original publication
GLP-1 receptor agonists and clinical outcomes in patients with type 2 diabetes undergoing transcatheter aortic valve implantation. Eur Heart J Qual Care Clin Outcomes. Published 8 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →